In 2013, the researchers found a rare disease - neonatal premature aging, and at that time, the researchers conducted a series of whole genome and exon sequencing to find the cause, the researchers Chopra, long-term commitment to energy metabolism disorders research, the study researchers found the cause of neonatal premature aging special genetic mutations, but how these mutations cause disease causes them it was not clear, then the researchers in the lab has carried on the related research, found that patients with these mutations can inhibit the body produces an unknown.
The newly discovered hormone called asprosin, which appears to be produced by white fat, is the c-terminal shear of profibrillin, which is the level of the nanomole in the body.
However, when it enters the liver, activate the G protein - cAMP - PKA pathway, allowing the liver to release glucose into the bloodstream.
If asprosin is unusually low in NPS patients, it is not possible to complete this task, showing hypoglycemia.
Compared to normal asprosin individuals, hyperglycemia and high insulin levels of obesity/diabetes individual asprosin hormone levels in the body tend to be higher, and based on this information, the researchers decided to develop a antibody, can resist asprosin is using specific antibodies to counteract asprosin, and this process is called immune isolation, which may help reduce the release of glucose levels in patients with liver, so as to promote the pancreas cells release a small amount of insulin.
To test this concept, scientists used the antibodies to treat diabetes, and found that even a single dose of antibodies worked well, reducing their blood sugar to a normal range.
When they treated mice longer, their insulin resistance was completely normalized.
In 2008 around 347 million people worldwide were estimated to have diabetes, with type 2 diabetes accounting for about 90 percent of all cases of diabetes.
Prevalence is still on the rise, especially in low - and middle-income countries.
In total, about 1.5 million people died directly from the disease in 2012, and more than 80 percent of those deaths occurred in low - and middle-income countries.
According to who projections, diabetes will be the seventh leading cause of death by 2030.
If people with diabetes to resist asprosin antibody response as well as diabetic mice, so the study is likely to help scientists develop a new type of diabetes therapy, asprosin found will largely improve the pressure and pain in patients with type 2 diabetes, by changing the affect glucose metabolism substance, thus achieve the purpose of the control blood sugar, provides a new way and method for diabetes treatment.
And asprosin can be targeted to treat diseases that affect many people, so this new hormone has a promising future.
prev:New progress in the study of blood sugar regulation(2017-08-22)
next:Obesity may be suppressed(2017-08-23)